Latest Archer Materials (ASX:AXE) News

Archer Materials made significant strides in quantum chip fabrication and quantum neural network fraud detection, while progressing its Biochip beta prototype. A $7 million placement post-quarter strengthens its financial position to accelerate development and commercialisation.

A tiny gold explorer, a battery materials stock and a biotech name led a week packed with dealmaking, drilling news and fresh funding. Resources did most of the heavy lifting, while several big gaps either held firm or gave back part of their early jump.

Big swings hit ASX tech as tiny GCM surged, Objective slumped on a Defence contract loss, and DXN fell despite landing new work. Away from the biggest price moves, the week was packed with raisings, acquisitions and fresh AI, quantum and enterprise contract news.

Archer Materials has raised $7 million through a placement and launched a $3 million share purchase plan, backing its strategic partnership with IonQ to develop sovereign quantum computing in Australia.

Archer Materials has secured a three-year strategic deal with IonQ, the global quantum computing leader, gaining access to advanced quantum cloud services and exploring onshore deployment of quantum hardware in Australia.

Big contract wins and fresh capital drove the strongest gains in local tech, led by FirstWave, Megaport and Aristocrat Leisure. Smaller speculative names were less stable, with several gap re-openings losing steam as investors sold into early excitement.

Archer Materials progresses its Biosensor platform from alpha to beta prototype, targeting manufacturability and external validation with expanded diagnostic applications including lithium monitoring.

Archer Materials is progressing toward demonstrating a working qubit this year while scaling quantum device fabrication from lab prototypes to wafer-scale manufacturing using semiconductor industry standards.

Small-cap tech shares swung hard this week as investors chased fresh funding, new contracts and launch news. The biggest winners kept rising after early jumps, while DroneShield fell despite record cash receipts as leadership changes unsettled traders.

Archer Materials has progressed its Biochip program by completing the alpha prototype and Stage 1 project with IMEC, now advancing to develop a beta prototype suitable for external use and clinical validation.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.